FDA orders a rare sudden-vision-loss warning on all GLP-1 drugs
A Drug Safety Communication dated Nov. 9 says a meta-analysis of 126 trials found 6.4 cases of NAION per 100,000 person-years among patients on GLP-1 medicines, compared with 3.8 on placebo or other diabetes drugs. The agency is requiring a Warnings and Precautions label change for the entire class, including Ozempic, Wegovy, Mounjaro and Zepbound.
As of 4:27 p.m. ET, Friday, Nov. 13, 2026
The Food and Drug Administration is requiring a new warning on all glucagon-like peptide-1 receptor agonist medicines, the widely used class that includes Ozempic, Wegovy, Mounjaro and Zepbound, about a potential increased risk of a rare optic-nerve condition that can cause sudden, sometimes permanent vision loss.
In a Drug Safety Communication dated Nov. 9, the agency said it is requiring application holders to add information to the Warnings and Precautions section of labeling about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION, associated with GLP-1 medicines. NAION, the FDA said, is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. The Associated Press also reported the class-wide labeling order, in an account carried Thursday by WUSF.
The agency said a meta-analysis of 126 randomized, controlled clinical trials, covering 134,253 patients and 288,879 person-years of exposure, found 6.4 NAION cases per 100,000 person-years among patients treated with GLP-1 medicines, compared with 3.8 cases per 100,000 person-years among patients who received a placebo or a non-GLP-1 glucose-lowering drug. Reviewers identified 15 probable NAION events in those trials: 10 in patients on GLP-1 medicines and 5 in patients on placebo, and none in patients on other non-GLP-1 diabetes drugs. Based on published literature, the FDA said, the incidence of NAION in the general population is 2.3 to 10.2 cases per 100,000 persons per year in adults older than 50.
The FDA also described a retrospective study in its Sentinel Real-World Evidence Data Enterprise commercial network that did not find a statistically significant increase in NAION risk when GLP-1 medicines were compared with SGLT-2 inhibitors (hazard ratio 1.19, 95% confidence interval 0.91 to 1.54), but did find an increased risk compared with DPP-4 inhibitors (hazard ratio 1.43, 95% confidence interval 1.02 to 2.01). After reviewing clinical trial, observational and postmarketing data, the agency concluded there is a potential increased risk of rare NAION events in patients taking GLP-1 medicines and said cases have been reported for all currently marketed products in the class. It said a review of available animal data did not identify a mechanism for how the drugs could increase that risk. The agency said it began a broader evaluation after a 2024 published study of semaglutide, while identifying several limitations of that study.
The FDA said patients who develop sudden, painless vision loss or other visual disturbances in one eye should contact a health care professional right away, and that if NAION is suspected they should be referred promptly to an ophthalmologist. It told clinicians to consider discontinuing the GLP-1 medicine in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk. Patients who have already had a NAION event should talk with their clinician about whether to continue the drug, the agency said. The labeling order applies to the entire class. The FDA’s table of approved GLP-1 medicines includes semaglutide products such as Ozempic, Wegovy and Rybelsus; tirzepatide products such as Mounjaro and Zepbound; older medicines such as liraglutide and dulaglutide; and the 2026-approved orforglipron product Foundayo.
Sources
- U.S. Food and Drug Administration, “FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition,” Drug Safety Communication, Nov. 9, 2026, rechecked Nov. 13, 2026 (read in full; used for the class-wide Warnings and Precautions order, the description of NAION, the 6.4 versus 3.8 per 100,000 person-years figures from the 126-trial analysis, the Sentinel study results, the table of approved products, and the agency’s advice to patients and clinicians)
- Associated Press, “FDA adds rare vision-loss warning to popular GLP-1 drugs,” Nov. 9, 2026, via WUSF, published Nov. 12, 2026, 10:34 p.m. ET (read in full; used for the wire’s Monday account of the class-wide labeling order)




